DISRUPTIVE ANTI-INFECTIVE TECHNOLOGIES ContraFect is developing first-in-class biologic therapies for life-threatening, drug-resistant infectious diseases. NEWS & EVENTS NOV 15, 2021 ContraFect Reports Third Quarter 2021 Financial Results and Provides Corporate Update Read More » NOV 9, 2021 ContraFect’s New Data Presented at NACFC Demonstrate Potential of Direct Lytic Agents to Treat Pulmonary Infections in Patients with Cystic Fibrosis Read More » SEE ALL NEWS & EVENTS » ABOUT ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides. We believe DLAs provide the opportunity to make meaningful improvements to clinical outcomes and to change the treatment paradigm for patients infected with antibiotic-resistant bacteria. Our initial product candidates are new agents to treat lethal, resistant infections such as methicillin-resistant Staph aureus (MRSA) and Gram-negative pathogens like multi-drug resistant (MDR) Pseudomonas aeruginosa. LEARN MORE » MEDIA COVERAGE ContraFect advancing new modality for antibiotic-resistant infections BioTuesdays View » Lysins Unlimited: Phages’ Secret Weapon Genetic Engineering & Biotechnology News View » The Virtuous Side of Viruses Scientific American View » TECHNOLOGY We leverage our lysin and amurin peptide platforms to develop innovative new therapies. VIEW TECHNOLOGY » VIEW PRODUCT PIPELINE » LEADERSHIP Our leadership team has a track record of creating shareholder value. MANAGEMENT BOARD OF DIRECTORS ROGER J. POMERANTZ, M.D., F.A.C.P. President, Chief Executive Officer and Chairman of the Board Dr. Pomerantz has served as Chairman of our board of directors and our Chief Executive Officer since April 2019. Prior to that, he had served as Vice Chairman of our board of directors since May 2014. From November 2013 to Dece... VIEW FULL PROFILE » STOCK INFORMATION DATA IS 15 MINUTES DELAYED ContraFect Corporation — Common Stock NASDAQ: CFRX Price Change Market Cap Volume View Our INVESTOR RELATIONS View Our SEC FILINGS © 2021 ContraFect Corporation. All Rights Reserved. COPYRIGHT PRIVACY POLICY EXPANDED ACCESS POLICY DISCLAIMER SITE MAP LINKEDIN TWITTER